Asthma Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma
Verified date | October 2022 |
Source | Akeso |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate-to-severe asthma.
Status | Terminated |
Enrollment | 1 |
Est. completion date | August 5, 2022 |
Est. primary completion date | August 5, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Key Inclusion Criteria: 1. Male or female subjects aged =18 years old and =75 years old; 2. Asthma was diagnosed = 12 months before screening, current stable treatment with medium-to-high-dose inhaled glucocorticoids plus up to two additional controllers = 3 months; 3. Blood eosinophil= 200 cells per microliter within 6 months before screening; 4. During the screening, 40% of the predicted normal value < pre-bronchodilator FEV1 < 80% of the predicted normal value, within 12 months before randomization, reversible airflow restriction was recorded; 5. Asthma was inadequately controlled; 6. For women with childbearing potential, they are not pregnant or lactating, and the subjects and their partners voluntarily take effective contraceptive measures judged by the investigators during the treatment and at least 3 months after last dose. Key Exclusion Criteria: 1. Subjects with lung diseases other than asthma, which may affect the subject's health or end point evaluation of the study; 2. Subjects had severe exacerbation events or systemic glucocorticoids usage within 1 month before randomization; 3. Respiratory tract infection and any serious infection within 1 month before randomization; 4. Subjects with parasitic infection, active tuberculosis infection, Hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or syphilis positive confirmation test; 5. Known or suspected history of immunosuppression; 6. History of malignant tumors; 7. A history of smoking: those who had quit smoking for = 6 months before screening, or smoking history > 10 pack per year; 8. Previous treatment with interleukin-4 (IL-4) or interleukin-13 (IL-13) inhibitors, and inadequate washout period of other biologic therapy; 9. Allergen immunotherapy within 3 months before randomization; 10. Progressive or uncontrolled other diseases or any other conditions or abnormal laboratory tests for which the investigator assess that the subjects are not suitable to enrol in the study. |
Country | Name | City | State |
---|---|---|---|
China | Baogang Hospital, Inner Mongolia, China | Baotou | Inner Mongolia |
China | Beijing Jingmei General Hospital | Beijing | Beijing |
China | Cangzhou People's Hospital | Cangzhou | Hebei |
China | Jilin Province People's Hospital | Changchun | Jilin |
China | The First Affiliated Hospital of Guangzhou Medical University | Guangzhou | Guangdong |
China | The Third Affiliated Hospital of Guangzhou Medical University | Guangzhou | Guangdong |
China | The Second Affiliated Hospital Zhejiang University School of Medicine, | Hangzhou | Zhejiang |
China | The Second Hospital of Anhui Medical University | Hefei | Anhui |
China | Inner Mongolia People's Hospital | Hohhot | Inner Mongolia |
China | Luoyang Central Hospital | Luoyang | Henan |
China | Jiangxi Provincial Prople's Hospita | Nanchang | Jiangxi |
China | Zhongda Hospital Southeast University | Nanjing | Jiangsu |
China | Jiangxi Pingxiang People's Hospital | Pingxiang | Jiangxi |
China | Shanghai General Hospital | Shanghai | Shanghai |
China | Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine | Shanghai | Shanghai |
China | Zhongshan Hospital Fudan University | Shanghai | Shanghai |
China | The Second Hospital of Hebei Medical University | Shijiazhuang | Hebei |
China | First Hospital of Shanxi Medical University | Taiyuan | Shanxi |
China | Henan Provincial People's Hospital | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Akeso |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in pre-bronchodilator forced expiratory volume in 1 second (FEV1) from baseline at week 12. | At week 12 | ||
Secondary | Annualized rate of severe exacerbation events within 24 weeks. | Baseline to Week24 | ||
Secondary | Annualized rate of severe exacerbation events within 32 weeks. | Baseline to Week32 | ||
Secondary | Change in pre-bronchodilator FEV1 from baseline to week 32. | Baseline to Week32 | ||
Secondary | Percentage change in pre-bronchodilator FEV1 from baseline to week 32. | Baseline to Week32 | ||
Secondary | Change in post-bronchodilator FEV1 from baseline to week 32. | Baseline to Week32 | ||
Secondary | Change in fractional exhaled nitric oxide (FeNO) from baseline to week 32. | Baseline to Week32 | ||
Secondary | Changes in asthma control questionnaire (ACQ-5) scores from baseline to week 32. | Baseline to Week32 | ||
Secondary | Change in standardized version of the asthma quality of life (AQLQ-s) scores from baseline at week 12 and 24. | at week 12,week 24 | ||
Secondary | Safety assessment: treatment-emergent adverse events (TEAE), serious adverse events (SAE) . | Baseline to Week32 | ||
Secondary | Pharmacokinetics (PK): AK120 concentration at different time points. | Baseline to Week32 | ||
Secondary | Immunogenicity assessment: number and percentage of subjects with detectable anti-AK120 antibody (ADA). | Baseline to Week32 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|